Companies · Pharmaceuticals

IntelGenx Technologies Corp.

VILLE SAINT LAURENT · Pharmaceuticals

Diligence memoA one-page analyst read on IntelGenx Technologies Corp. — recommendation, valuation, rhythm, risks.
$8.8M
Total raised · real
5
Rounds
0.4×
Latest step-up
Top 49%
Sector rank · raised
Seed
Latest stage · inferred · Tue Mar 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

IntelGenx Technologies Corp. looks fair against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.73× the median modeled value of Seed Pharmaceuticals companies in 2022–2024 (50 peers) — value vs value, same stage and era.
  • Within the normal band (73% of peer median) for its niche.
At-risk
  • Last raise 3.3 yr ago; this sector typically re-raises about every 13 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

IntelGenx Technologies Corp. is one of 1610 Pharmaceuticals companies tracked from VILLE SAINT LAURENT. By capital raised it ranks mid-pack (ahead of 52% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
26
Investors (latest)
2023-03-21
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$25M$50M$75M$100MSeed · 2011-06-21 Raised $1.7M (real) Modeled valuation $66M (est)Seed2011Seed · 2011-06-21 Raised $1.7M (real) Modeled valuation $66M (est)Seed2011Seed · 2018-05-08 Raised $2.5M (real) Modeled valuation $94M (est)Seed2018Seed · 2020-10-15 Raised $1.8M (real) Modeled valuation $58M (est)Seed2020Seed · 2021-08-05 Raised $2.1M (real) Modeled valuation $45M (est)Seed2021Seed · 2021-08-05 Raised $2.1M (real) Modeled valuation $45M (est)Seed2021Seed · 2023-03-21 Raised $763K (real) Modeled valuation $7.1M (est)Seed2023+$1.7M+$2.5M+$1.8M+$2.1M+$2.1M+$763KCumulative $13M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$1.7M · 2011
Seed extension$1.7M · 2011
Seed extension$2.5M · 2018
Seed extension$1.8M · 2020
Seed extension$2.1M · 2021
Seed extension$2.1M · 2021
Seed extension$763K · 2023

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$7.1M
Base estimate est.
$577K
Conservative case
$26.5M
Upside case
$3.8M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Seed · modeled $65.8M · 2011-06-212011Seed · modeled $65.8M · 2011-06-21Seed · modeled $94.3M · 2018-05-08Seed · modeled $57.6M · 2020-10-15Seed · modeled $45.2M · 2021-08-05Seed · modeled $45.2M · 2021-08-05Seed · modeled $7.1M · 2023-03-212023
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
34%
Survival probability
15% low · 52% high
1.68×/yr
Annual markup
2.20×/yr upside case
3.3 yr
Elapsed time used
3.3 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
23 mo
Avg between rounds
$752K/yr
Capital velocity
15.0 yr
On record since
2011
First round
7
Rounds on file
How it compares to the market

Benchmarked against 1610 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.1× above median
This company$8.8M
Sector median$8.1M
Latest round — vs other Seed rounds in sector (real $, this stage) 0.5× of median
This company$763K
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 0.1× of median
This company$7.1M
Sector median$76.1M

Raised more than 52% of sector peers (real $). Modeled value above 12% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #33 of 50.

This companyCohort peer
$1.0M$10.0M$100.0M$1.0M$10.0M$100.0MCapital raised (log)Celeris Therapeutics, Inc. · Seed Raised $3.0M · modeled $48.6M (est)Oligomerix, Inc. · Seed Raised $8.3M · modeled $37.8M (est)2A Biosciences, Inc. · Seed Raised $3.8M · modeled $36.0M (est)Myosin Therapeutics Inc. · Seed Raised $3.0M · modeled $32.4M (est)Eluciderm Inc. · Seed Raised $3.8M · modeled $31.7M (est)AION Healthspan, Inc. · Seed Raised $2.9M · modeled $28.5M (est)Cannabinoid API Solutions, LLC · Seed Raised $2.2M · modeled $27.4M (est)CanaQuest Medical Corp. · Seed Raised $2.0M · modeled $22.8M (est)M Chest Institutional Pharmacy Group, LLC · Seed Raised $3.7M · modeled $21.4M (est)Vitalis Therapeutics, Inc. · Seed Raised $2.0M · modeled $20.8M (est)Visiox Pharma, LLC · Seed Raised $1.3M · modeled $17.5M (est)Adtech Pharma, Inc. · Seed Raised $3.0M · modeled $16.9M (est)IntelGenx Technologies Corp. (this company) Raised $8.8M · modeled $7.1M (est)IntelGenx Technologies Corp.
CompanyStageRaised · realValue · estvs peer med.
Celeris Therapeutics, Inc.Seed$3.0M$48.6M5.06×
Oligomerix, Inc.Seed$8.3M$37.8M3.93×
2A Biosciences, Inc.Seed$3.8M$36.0M3.74×
Myosin Therapeutics Inc.Seed$3.0M$32.4M3.37×
Eluciderm Inc.Seed$3.8M$31.7M3.29×
AION Healthspan, Inc.Seed$2.9M$28.5M2.96×
Cannabinoid API Solutions, LLCSeed$2.2M$27.4M2.85×
CanaQuest Medical Corp.Seed$2.0M$22.8M2.37×
M Chest Institutional Pharmacy Group, LLCSeed$3.7M$21.4M2.22×
Vitalis Therapeutics, Inc.Seed$2.0M$20.8M2.16×
Visiox Pharma, LLCSeed$1.3M$17.5M1.82×
Adtech Pharma, Inc.Seed$3.0M$16.9M1.76×
IntelGenx Technologies Corp. this companySeed$8.8M$7.1M0.73×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$1.7M2011-06-21$8.7M$65.8M85%
Seed$1.7M2011-06-21$8.7M$65.8M85%
Seed$2.5M2018-05-08$12.4M$94.3M90%
Seed$1.8M2020-10-15$8.8M$57.6M90%
Seed$2.1M2021-08-05$10.5M$45.2M90%
Seed$2.1M2021-08-05$10.5M$45.2M90%
Seed$763K2023-03-21$3.8M$7.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$1.7M2011-06-21
    • First recorded raise — entered as Seed.
    • 20 investors on this round.
  2. Seed$1.7M2011-06-21
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 20 investors on this round.
  3. Seed$2.5M2018-05-08
    • Raised again after 83 mo — slower than the ~13 mo sector norm.
    • Round 1.4× larger than the prior — scaling up.
    • Switched to Rule 506(b) (was Rule 06).
    • 38 investors on this round.
  4. Seed$1.8M2020-10-15
    • Raised again after 29 mo — slower than the ~13 mo sector norm.
    • Round 1.4× smaller than the prior — bridge or down round.
    • 53 investors on this round.
  5. Seed$2.1M2021-08-05
    • Raised 10 mo later, in step with the ~13 mo sector norm.
    • Round roughly the size of the prior one.
    • 34 investors on this round.
  6. Seed$2.1M2021-08-05
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 34 investors on this round.
  7. Seed$763K2023-03-21
    • Raised again after 19 mo — slower than the ~13 mo sector norm.
    • Round 2.8× smaller than the prior — bridge or down round.
    • 26 investors on this round.
Intelligence
2025 ~Q1
Modeled next raise · ~23mo cadence
$763K
Modeled next size est.range $763K$1.2M
0.4×
Last step-up
$752K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Andre Godin1 other2018-05
Andre G. Godin2020-10
Bernd J. Melchers2011-06
Bernd Melchers2018-05
Clemens J. Mayr2020-10
Clemens Mayr2018-05
Frank J. Stegert2021-08
Horst G. Zerbe2011-06
Horst Zerbe2018-05
Ian A. Troup2011-06
Ingrid J. Zerbe2011-06
J. Bernard A. Boudreau2011-06
J. Bernard Boudreau2018-05
J. Bernard G. Boudreau2020-10
John J. Marinucci2011-06
John Marinucci2018-05
Mark J. Nawacki2020-10
Mark Nawacki2018-05
Monika J. Trzcinska2023-03
Paul A. Simmons2011-06
Rajiv J. Khosla2011-06
Srinivas J. Rao2021-08
Registry & provenance

IntelGenx Technologies Corp. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1098880
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Lipella Pharmaceuticals Inc.PharmaceuticalsSeed$8.2M$9.6Msame sector · same stage
Immunophotonics, Inc.PharmaceuticalsSeed$8.1M$8.6Msame sector · same stage
Aponia Laboratories IncPharmaceuticalsSeed$7.7M$2.7Msame sector · same stage
Cardax, Inc.PharmaceuticalsSeed$7.3M$4.1Msame sector · same stage
FibroBiologics, Inc.PharmaceuticalsSeed$7.2M$3.8Msame sector · same stage
Urigen Pharmaceuticals, Inc.PharmaceuticalsSeed$7.1M$6.3Msame sector · same stage
Amytrx Therapeutics, Inc.PharmaceuticalsSeed$7.0M$4.6Msame sector · same stage
Fluoropharma Medical, Inc.PharmaceuticalsSeed$11.2M$5.7Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Intellipharmaceutics International Inc.PharmaceuticalsSeries A$31.4M87%
Vogenx, Inc.PharmaceuticalsPre-Seed$1.5M87%
Vapogenix, Inc.PharmaceuticalsSeries A$50.6M84%
Aptinyx Inc.PharmaceuticalsSeries C$2.5B84%
Tyme Technologies, Inc.PharmaceuticalsSeries B$680.1M84%
MBX Biosciences, Inc.PharmaceuticalsSeries C$723.4M83%
Torigen Pharmaceuticals, Inc.PharmaceuticalsSeries A$62.0M83%
Med Aditus Pharmaceuticals, Inc.PharmaceuticalsSeries A$22.0M83%
Frequently asked
How much funding has IntelGenx Technologies Corp. raised?
IntelGenx Technologies Corp. has raised approximately $8.8M in disclosed capital across 5 recorded financing rounds, aggregated from public filings.
What is IntelGenx Technologies Corp.'s estimated valuation?
Provath's modeled valuation for IntelGenx Technologies Corp. is approximately $7.1M (modeled range $577K–$26.5M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is IntelGenx Technologies Corp. at?
IntelGenx Technologies Corp.'s latest modeled financing stage is Seed. Its most recent recorded round closed around Tue Mar 21.
What does IntelGenx Technologies Corp. do and where is it based?
IntelGenx Technologies Corp. operates in the Pharmaceuticals sector, based in VILLE SAINT LAURENT.
Explore related

See where IntelGenx Technologies Corp. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at IntelGenx Technologies Corp., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.